These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1402 related articles for article (PubMed ID: 27118452)

  • 1. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
    Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
    Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
    Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
    J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30
    Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B
    Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.
    Kebriaei P; Huls H; Jena B; Munsell M; Jackson R; Lee DA; Hackett PB; Rondon G; Shpall E; Champlin RE; Cooper LJ
    Hum Gene Ther; 2012 May; 23(5):444-50. PubMed ID: 22107246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
    Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
    J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
    J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
    Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
    Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice.
    Chen R; Wang M; Liu Q; Wu J; Huang W; Li X; Du B; Xu Q; Duan J; Jiao S; Lee HS; Jung NC; Lee JH; Wang Y; Wang Y
    Cancer Lett; 2020 Jan; 469():162-172. PubMed ID: 31634527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.
    Xin X; Zhu X; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Li C; Cao Y; Meng F; Jiang L; Zhang Y
    Cell Oncol (Dordr); 2024 Aug; 47(4):1425-1440. PubMed ID: 38564164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.
    Wang L; Fang C; Kang Q; Huang W; Chen Z; Zhao W; Wang L; Wang Y; Tan K; Guo X; Xu Y; Wang S; Wang L; Qiao J; Tang Z; Yu C; Xu Y; Li Y; Yu L
    Blood Cancer J; 2024 Aug; 14(1):130. PubMed ID: 39112452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.